[HTML][HTML] Signal pathways of melanoma and targeted therapy
W Guo, H Wang, C Li - Signal transduction and targeted therapy, 2021 - nature.com
Melanoma is the most lethal skin cancer that originates from the malignant transformation of
melanocytes. Although melanoma has long been regarded as a cancerous malignancy with …
melanocytes. Although melanoma has long been regarded as a cancerous malignancy with …
Rho GTPase signaling in cancer progression and dissemination
E Crosas-Molist, R Samain… - Physiological …, 2022 - journals.physiology.org
Rho GTPases are a family of small G proteins that regulate a wide array of cellular
processes related to their key roles controlling the cytoskeleton. Cancer is a multistep …
processes related to their key roles controlling the cytoskeleton. Cancer is a multistep …
[HTML][HTML] RHOJ controls EMT-associated resistance to chemotherapy
M Debaugnies, S Rodríguez-Acebes, J Blondeau… - Nature, 2023 - nature.com
The resistance of cancer cells to therapy is responsible for the death of most patients with
cancer. Epithelial-to-mesenchymal transition (EMT) has been associated with resistance to …
cancer. Epithelial-to-mesenchymal transition (EMT) has been associated with resistance to …
[HTML][HTML] Targeted therapy in melanoma and mechanisms of resistance
The common mutation BRAFV600 in primary melanomas activates the mitogen-activated
protein kinase/extracellular-signal-regulated kinase (MAPK/ERK) pathway and the …
protein kinase/extracellular-signal-regulated kinase (MAPK/ERK) pathway and the …
[HTML][HTML] Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy
Q Li, Z Li, T Luo, H Shi - Molecular biomedicine, 2022 - Springer
Abstract The PI3K/AKT/mTOR and RAF/MEK/ERK pathways are commonly activated by
mutations and chromosomal translocation in vital targets. The PI3K/AKT/mTOR signaling …
mutations and chromosomal translocation in vital targets. The PI3K/AKT/mTOR signaling …
BRAF—A tumour-agnostic drug target with lineage-specific dependencies
In June 2022, the FDA granted Accelerated Approval to the BRAF inhibitor dabrafenib in
combination with the MEK inhibitor trametinib for the treatment of adult and paediatric …
combination with the MEK inhibitor trametinib for the treatment of adult and paediatric …
Epithelial–mesenchymal transition: The history, regulatory mechanism, and cancer therapeutic opportunities
Epithelial–mesenchymal transition (EMT) is a program wherein epithelial cells lose their
junctions and polarity while acquiring mesenchymal properties and invasive ability …
junctions and polarity while acquiring mesenchymal properties and invasive ability …
[HTML][HTML] Mechanisms of acquired BRAF inhibitor resistance in melanoma: a systematic review
I Proietti, N Skroza, N Bernardini, E Tolino, V Balduzzi… - Cancers, 2020 - mdpi.com
Simple Summary Patients with advanced melanoma are often treated with v-raf murine
sarcoma viral oncogene homolog B1 (BRAF) inhibitors. Although these agents prolong life …
sarcoma viral oncogene homolog B1 (BRAF) inhibitors. Although these agents prolong life …
[HTML][HTML] Rac1, a potential target for tumor therapy
J Liang, L Oyang, S Rao, Y Han, X Luo, P Yi… - Frontiers in …, 2021 - frontiersin.org
RAS-related C3 botulinum toxin substrate 1 (Rac. 1) is one of the important members of Rho
GTPases. It is well known that Rac1 is a cytoskeleton regulation protein that regulates cell …
GTPases. It is well known that Rac1 is a cytoskeleton regulation protein that regulates cell …
[HTML][HTML] Cytotoxic lymphocytes target characteristic biophysical vulnerabilities in cancer
Immune cells identify and destroy tumors by recognizing cellular traits indicative of
oncogenic transformation. In this study, we found that myocardin-related transcription factors …
oncogenic transformation. In this study, we found that myocardin-related transcription factors …